BQ Prime's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer BQ Prime's subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Eris Lifesciences Ltd. delivered an operationally inline Q4 FY22. It ended the second consecutive year with earnings growth in the a healthy teens compared to stable earnings over FY18-20.
The acquisition of Oaknet Healthcare enables Eris Lifesciences to add a dermatology franchise, expand into the cosmetology space, and improve synergy in the women's healthcare segment.
We tweaked our FY23/FY24 earnings per share estimate by (3%)/2% to factor in:
addition of the Oaknet business,
scale-up in already launched products (Drolute, Xsulin, Zomelis, Gluxit),
strong pace of launches over the next 12-15 months, and
upcoming promotional expenses
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
